Premium
Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy
Author(s) -
Zschüntzsch Jana,
Zhang Yaxin,
Klinker Florian,
Makosch Gregor,
Klinge Lars,
Malzahn Dörthe,
Brinkmeier Heinrich,
Liebetanz David,
Schmidt Jens
Publication year - 2016
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/jnc.13269
Subject(s) - duchenne muscular dystrophy , creatine kinase , medicine , dystrophin , skeletal muscle , mdx mouse , muscular dystrophy , endocrinology , inflammation , antibody , myopathy , neuromuscular disease , immunology , disease
Duchenne muscular dystrophy ( DMD ) is a severe hereditary myopathy. Standard treatment by glucocorticosteroids is limited because of numerous side effects. The aim of this study was to test immunomodulation by human immunoglobulin G (IgG) as treatment in the experimental mouse model (mdx) of DMD . 2 g/kg human IgG compared to human albumin was injected intraperitoneally in mdx mice at the age of 3 and 7 weeks. Advanced voluntary wheel running parameters were recorded continuously. At the age of 11 weeks, animals were killed so that blood, diaphragm, and lower limb muscles could be removed for quantitative PCR , histological analysis and ex vivo muscle contraction tests. IgG compared to albumin significantly improved the voluntary running performance and reduced muscle fatigability in an ex vivo muscle contraction test. Upon IgG treatment, serum creatine kinase values were diminished and m RNA expression levels of relevant inflammatory markers were reduced in the diaphragm and limb muscles. Macrophage infiltration and myopathic damage were significantly ameliorated in the quadriceps muscle. Collectively, this study demonstrates that, in the early disease course of mdx mice, human IgG improves the running performance and diminishes myopathic damage and inflammation in the muscle. Therefore, IgG may be a promising approach for treatment of DMD .Two monthly intraperitoneal injections of human immunoglobulin G (IgG) improved the early 11‐week disease phase of mdx mice. Voluntary running was improved and serum levels of creatine kinase were diminished. In the skeletal muscle, myopathic damage was ameliorated and key inflammatory markers such as mRNA expression of SPP1 and infiltration by macrophages were reduced. The study suggests that IgG could be explored as a potential treatment option for Duchenne muscular dystrophy and that pre‐clinical long‐term studies should be helpful.